Ratings by Maxim Group (Caroline Palomeque)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 9/4/2025 | Dare Bioscience | DARE | Upgrade | Buy (Hold) |
2.06 (2.04) |
-0.97% | Details | |
| 8/14/2024 | Dare Bioscience | DARE | Downgrade | Hold (Buy) |
4.20 (2.06) |
-50.95% | Details | |
| 9/22/2023 | Agile Therapeutics | AGRX | Upgrade | Buy (Hold) |
1.73 (1.51) |
-12.72% | Details | |
| 8/7/2023 | VistaGen Therapeutics | VTGN | Upgrade | Buy (Hold) |
1.68 (4.36) |
159.52% | Details | |
| 3/24/2023 | Agile Therapeutics | AGRX | Downgrade | Hold (Buy) |
0.24 (1.51) |
529.17% | Details | |
| 7/26/2022 | Agile Therapeutics | AGRX | Upgrade | Buy (Hold) |
0.50 (1.51) |
202% | Details | |
| 7/26/2022 | VistaGen Therapeutics | VTGN | Downgrade | Hold (Buy) |
0.18 (0.65) |
261.11% | Details | |
| 4/8/2022 | Agile Therapeutics | AGRX | Downgrade | Hold (Buy) |
0.16 (1.51) |
843.75% | Details | |
| 1/18/2022 | Dare Bioscience | DARE | Maintain | Buy (N/A) |
|
Details | ||
| 4/21/2021 | Cerecor | CERC | Upgrade | Buy (Hold) |
2.34 (2.93) |
25.21% | Details | |
| 12/22/2020 | VistaGen Therapeutics | VTGN | Maintain | Buy (N/A) |
|
Details | ||
| 3/13/2020 | Cerecor | CERC | Downgrade | Hold (Buy) |
2.04 (2.93) |
43.63% | Details | |
| 2/18/2020 | Agile Therapeutics | AGRX | Maintain | Buy (N/A) |
|
Details | ||
| 11/14/2019 | VistaGen Therapeutics | VTGN | Maintain | Buy (N/A) |
|
Details | ||
| 7/16/2019 | Agile Therapeutics | AGRX | Maintain | Hold (N/A) |
|
Details | ||
| 4/9/2019 | Cerecor | CERC | New Coverage | Buy (N/A) |
5.63 (2.93) |
-47.96% | Details | |
| 4/1/2019 | Genprex | GNPX | Downgrade | Hold (Buy) |
1.55 (0.51) |
-67.1% | Details | |
| 2/14/2019 | AzurRx Biopharma | AZRX | New Coverage | Buy (N/A) |
1.81 (1.81) |
0% | Details | |
| 2/13/2019 | VistaGen Therapeutics | VTGN | Maintain | Buy (N/A) |
|
Details | ||
| 1/24/2019 | Bellerophon Therapeutics | BLPH | New Coverage | Buy (N/A) |
0.88 (0.01) |
-98.86% | Details | |
| 11/29/2018 | Agile Therapeutics | AGRX | New Coverage | Buy (N/A) |
0.80 (1.51) |
88.75% | Details | |
| 9/14/2018 | Genprex | GNPX | New Coverage | Buy (N/A) |
2.30 (1.55) |
-32.61% | Details | |
| 8/17/2018 | Dare Bioscience | DARE | New Coverage | Buy (N/A) |
1.01 (2.04) |
101.98% | Details |
